UK markets open in 7 hours 50 minutes

Spexis AG (PPHOF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.50000.0000 (0.00%)
At close: 12:21PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.5000
Open2.5000
BidN/A x N/A
AskN/A x N/A
Day's range2.5000 - 2.5000
52-week range2.5000 - 8.6626
Volume1,000
Avg. volume0
Market cap28.891M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-3.9800
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Polyphor closes merger with EnBiotix and is renamed Spexis

    Polyphor AG / Key word(s): Merger30-Dec-2021 / 07:15 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, December 30, 2021Polyphor closes merger with EnBiotix and is renamed SpexisPolyphor AG (SIX: POLN) and EnBiotix Inc. today announced the closing of the merger of the two companies and the change of name of the combined company to Spexis AG. Pursua

  • EQS Group

    Polyphor to inform about the financing of its merger partner EnBiotix

    Polyphor AG / Key word(s): Merger/Financing29-Dec-2021 / 07:30 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, December 29, 2021Polyphor to inform about the financing of its merger partner EnBiotix Polyphor AG (SIX: POLN) and EnBiotix Inc. today announced that EnBiotix has completed a convertible debenture raise of USD 11 million to finance its f

  • EQS Group

    Polyphor and EnBiotix announce dosing of first patient in a first-in-human clinical trial of inhaled murepavadin

    Polyphor AG / Key word(s): Study15-Dec-2021 / 07:15 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, December 15, 2021Polyphor and EnBiotix announce dosing of first patient in a first-in-human clinical trial of inhaled murepavadin Polyphor AG (SIX: POLN) and EnBiotix Inc. today announced that the first subjects have been dosed in the first-in-huma